Send us Feedback

Trubion Pharmaceuticals (TRBN)
Analysis
SUMMARY
BULLS
BEARS
TOPICS
Data
DATA CENTRAL
STOCK CHART
Financials
SEC FILINGS
BALANCE
INCOME
CASH FLOW
QUOTE AND NEWS
Trubion Pharma (TRBN) Granted Early Termination of HSR Waiting Period Related to Puchase by Emergent (EBS)
StreetInsider.com  Sep 8  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Trubion+Pharma+%28TRBN%29+Granted+Early+Termination+of+HSR+Waiting+Period+Related+to+Puchase+by+Emergent+%28EBS%29/5954301.html for the full story.
(TRBN) Trubion Pharmaceuticals Trims Size of Quarterly Loss
Stock Blog Hub  Aug 23  Comment 
Trubion Pharmaceuticals Inc. (TRBN) posted a loss of 28 cents per share during the second quarter of 2010, narrower than the Zacks Consensus Estimate for a loss of 34 cents and also narrower than the year-ago loss of 37 cents. Higher revenues...
Trubion Pharma (TRBN) Reports Q2 Loss of 28c, Beats by 6c; Guides FY10 Sales
StreetInsider.com  Aug 16  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Earnings/Trubion+Pharma+%28TRBN%29+Reports+Q2+Loss+of+28c%2C+Beats+by+6c%3B+Guides+FY10+Sales/5900673.html for the full story.
Lilly Dips On Court's Strattera Ruling
Forbes  Aug 13  Comment 
Eli Lilly is trading lower today after the company loses in patent litigation.
Biotech Stocks: PDL, Lilly slide; Trubion rallies on buyout
MarketWatch  Aug 13  Comment 
Shares of PDL Biopharma drop on news that Roche might discontinue certain royalty payments to the company.
Autodesk, DeVry, Dynegy, Rambus, Trubion: U.S. Equity Movers
BusinessWeek  Aug 13  Comment 
Shares of the following companies are having unusual moves in U.S. trading. Stock symbols are in parentheses, and prices are as of 9:50 a.m. in New York.
Emergent buys Trubion for up to $135M
FierceBiotech  Aug 13  Comment 
Emergent BioSolutions is buying Trubion Pharmaceuticals for $96.8 million up front and up to $38.7 million of success-based milestones. Emergent gains Trubion's two clinical-stage product candidates for oncology and autoimmunity. The company...
Trubion, ShoreTel: Volume Movers
TheStreet.com  Aug 13  Comment 
Several stocks trading below $5, including Trubion Pharmaceuticals, were poised to move on above-average volume Friday.
Pfizer Cuts Off Arthritis Drug
Forbes  Jun 15  Comment 
Pharma firm discontinues one of two drugs it is developing with Trubion.
Trubion slumps after Pfizer kills lead RA drug program
FierceBiotech  Jun 15  Comment 
Shares of Seattle-based Trubion Pharmaceuticals (TRBN) slumped after Pfizer announced that it was dumping the development program for its lead rheumatoid arthritis drug. TRU-015 had been Trubion's first shot at a best-in-class CD20 therapy that...




RELATED WIKI ARTICLES

Related Articles

more ▼WIKI ANALYSIS
 
TOP CONTRIBUTORS
Sr. Director
Grant Zeng
www.zacks.com

Trubion Pharmaceuticals, Inc. (TRBN) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutic medicines to treat autoimmune diseases and cancer. The company utilizes proprietary technology to develop drugs that are safer and more effective than currently available therapies.

Trubion's current product candidates are novel single-chain polypeptide proteins which are called small modular immunopharmaceutical (SMIP). These candidates are designed using the company's custom drug assembly technology. These product candidates bind to specific antigen targets on a cell's surface that have been clinically validated as important in disease management either by existing products or by potential products in clinical trials. Trubion's product candidates may offer the potential for safer and more effective therapies than existing or other potential products. In December 2005 Trubion entered into a collaboration agreement with Wyeth for the development and worldwide commercialization of certain therapeutics, including its lead product candidate, TRU-015. To date, none of its product candidates has been approved for marketing and sale and the company has not received any product revenue.

Trubion Pharmaceuticals, Inc. was originally formed in 1999 in the state of Washington as a limited liability company and reincorporated in October 2002 in the state of Delaware. In September 2003 the company changed its name to Trubion Pharmaceuticals, Inc. Trubion went public in October 2006 and is headquartered in Seattle, WA.


The following table summarizes the pipeline information of the company.



Product Candidate

Disease Indication

Development Stage

Partner







TRU-015

Rheumatoid Arthritis

Phase IIb, preliminary results presented

Wyeth



Systemic Lupus Erythematosus (SLE)

Preclinical

Wyeth



B-Cell Malignancies

Preclinical

Wyeth


TRU-016

B-Cell Malignancies

IND filed in 4Q07

None




References

Retrieved from "http://www.wikinvest.com/stock/Trubion_Pharmaceuticals_(TRBN)"
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki